India Zearalenone Antibody Market Size & Outlook, 2026-2034

India Zearalenone Antibody Market Insights

As per Deep Market Insights insights, the India Zearalenone Antibody Market stood at USD 138.8 Million in 2025 and is anticipated to grow to USD 508.69 Million by 2034.
The India market is expected to advance at a CAGR of 15.57% from 2026 through 2034.
In 2025, Monoclonal antibodies accounted for the highest share of the By Type market size.
During the forecast period, Recombinant antibodies is set to register the highest growth, making it the most lucrative By Type segment.

India accounted for 5.1% of the global Zearalenone Antibody Market size in 2025.
By 2034, United States is expected to remain the top global market in terms of size.
Within Asia Pacific, China is forecasted to dominate the regional Zearalenone Antibody Market size by 2034.
Taiwan will be the fastest-growing market in Asia Pacific, projected to achieve USD 122.45 Million by 2034.

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 138.8 Million
Market Size In 2034	USD 508.69 Million
Largest segment	Monoclonal antibodies
Units	Revenue in USD Million
CAGR	15.57% (2026-2034)
Segmnetation Covered
By Type	Monoclonal antibodies Polyclonal antibodies Recombinant antibodies Custom antibodies
By Application	Food safety testing Animal feed testing Research laboratories Diagnostic use
By Form	Liquid Lyophilized powder Conjugated antibodies Ready-to-use kits
By End User	Research institutes Food testing labs Biotech companies Academic institutions
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

By Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Monoclonal antibodies	XX.x	XX.x	XX.x	55.58	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Polyclonal antibodies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Recombinant antibodies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Custom antibodies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Application	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Food safety testing	XX.x	XX.x	XX.x	61.24	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Animal feed testing	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Research laboratories	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Diagnostic use	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Form	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Liquid	XX.x	XX.x	XX.x	63.7	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Lyophilized powder	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Conjugated antibodies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Ready-to-use kits	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By End User	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Research institutes	XX.x	XX.x	XX.x	60.8	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Food testing labs	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Biotech companies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Academic institutions	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x